Scientific article
Open access

The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey

Published inJournal of Alzheimer's disease, vol. 89, no. 2, p. 535-551
Publication date2022
First online date2022-09-13

Background: Recent advances occurred in the field of Alzheimer's disease (AD) biomarkers and the introduction of a research framework grounded on a biomarker-based definition of AD might have fostered an increased clinical use of AD biomarkers. For this reason, an up-to-date depiction of the clinical use of AD biomarkers is needed.

Objective: To investigate the clinical use of the main AD biomarkers in patients with mild cognitive impairment (MCI) by examining the beliefs and preferences of professionals (clinicians and biomarker experts) of the European Alzheimer's Disease Consortium (EADC).

Methods: 150 professionals filled in an online survey from May to September 2020. The investigated biomarkers were medial temporal lobe atrophy score (MTA) on structural MRI, typical AD (i.e., temporoparietal and posterior cingulate) hypometabolism on FDG-PET, CSF (Aβ42, p-tau, t-tau), amyloid-PET and tau-PET.

Results: The frequency of responders reporting a frequent-to-constant use of MTA (77%) is higher than that of those reporting a frequent-to-constant use of the other AD biomarkers (i.e.

, csf: 45%, p = 0.014; FDG-PET: 32%, p < 0.001; amyloid-PET: 8%, p < 0.001; and tau-PET: 2%, p < 0.001). CSF is considered the most valuable biomarker in terms of additional diagnostic value, followed by amyloid-PET, tau-PET, and typical AD hypometabolism on FDG-PET.

Conclusion: AD biomarkers are widely used across European memory clinics with a clinical research background for the diagnosis of MCI. Overall, we observed that CSF is currently considered as the most useful biomarker, followed by amyloid-PET.

  • APOE
  • Alzheimer’s disease
  • amyloid-PET
  • biomarkers
  • cerebrospinal fluid
  • clinical use
  • magnetic resonance imaging
  • mild cognitive impairment
  • tau-PET
  • Alzheimer Disease / diagnostic imaging
  • Amyloid beta-Peptides
  • Atrophy
  • Biomarkers
  • Cognitive Dysfunction / diagnostic imaging
  • Fluorodeoxyglucose F18
  • Humans
  • Pemetrexed
  • Peptide Fragments
  • Positron-Emission Tomography
  • tau Proteins
Citation (ISO format)
CAPRIOGLIO, Camilla et al. The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey. In: Journal of Alzheimer’s disease, 2022, vol. 89, n° 2, p. 535–551. doi: 10.3233/JAD-220333
Main files (1)
Article (Published version)
Secondary files (1)
ISSN of the journal1387-2877

Technical informations

Creation11/16/2022 12:55:36 PM
First validation07/04/2023 6:47:39 AM
Update time07/04/2023 6:47:39 AM
Status update07/04/2023 6:47:39 AM
Last indexation08/31/2023 11:54:24 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack